RGX-314 Gene Therapy for nAMD Well-Tolerated in Phase 1/2a Study

A single administration of ABBV-RGX-314 was generally well tolerated, with little to no supplemental anti-VEGF injections required in most patients at two years.

Related Keywords

Boston ,Massachusetts ,United States ,Jeffreys Heier , ,European Medicines Agency ,Regenxbio Inc ,Drug Administration ,Ophthalmic Consultants ,Vascular Endothelial Growth Factor Agents ,Retinal Disease ,From Bench ,